AI assistant
Sending…
PDS Biotechnology Corp — Director's Dealing 2017
Feb 24, 2017
34613_dirs_2017-02-24_7f45de4b-5de7-4263-a8c5-bf665cb5df30.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 3 — Initial Statement of Beneficial Ownership
Issuer: Edge Therapeutics, Inc. (EDGE)
CIK: 0001472091
Period of Report: 2017-02-21
Reporting Person: Wyant Alyssa (SVP Regulatory Affairs)
More from PDS Biotechnology Corp
Interim / Quarterly Report
2026
May 14
Regulatory Filings
2026
May 13
Regulatory Filings
2026
May 1
Regulatory Filings
2026
Apr 27
Regulatory Filings
2026
Apr 15
Regulatory Filings
2026
Mar 30
Director's Dealing
2026
Mar 3
Director's Dealing
2026
Mar 3
Director's Dealing
2026
Mar 3
Director's Dealing
2026
Mar 3